Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×COC with natural estrogen (quadriphasic)

Updated · Methodology

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Combined hormonal contraceptives raise the risk of venous thromboembolism compared with non-use. Epidemiological studies also link them to a higher risk of arterial thromboembolism, including myocardial infarction and stroke. Coagulation and fibrinolysis parameters can change, usually within the normal range (estradiol valerate/dienogest SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (estradiol valerate/dienogest SmPC, AEMPS). After the contraceptive is stopped, the effect of acenocoumarol can increase again, especially if its dose had been raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the estradiol valerate/dienogest summary of product characteristics (SmPC) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (estradiol valerate/dienogest SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. It is also contraindicated in known predisposition to arterial thromboembolism, such as antiphospholipid antibodies. The SmPC lists valvular heart disease and atrial fibrillation among risk factors for arterial thromboembolism. With several risk factors or one severe risk factor, the contraceptive is contraindicated (estradiol valerate/dienogest SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). The US label contraindicates estradiol valerate/dienogest in women at high risk of arterial or venous thrombotic disease. Examples include current or past deep vein thrombosis or pulmonary embolism and thrombogenic valvular or rhythm disease of the heart, such as atrial fibrillation (estradiol valerate/dienogest prescribing information, US Food and Drug Administration, FDA). If venous or arterial thromboembolism is suspected or confirmed, stop the contraceptive. If anticoagulant treatment is started, switch to a suitable alternative contraceptive method, because coumarins are teratogenic (estradiol valerate/dienogest SmPC, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol